Find Funding Opportunities

Notice Intent Publish Funding Opportunity Announcement Clinical Trials Network Pain - Clinical Coordinating Center U24 Clinical Trial Optional) Notice Number: NOT-NS-18-058 Key Dates Release Date:June 14, 2018 Estimated Publication Date Funding Opportunity Announcement: 07/16/2018 First Estimated Application Due Date: 09/14/2018 Earliest Estimated Award Date: 12/04/2018 Earliest Estimated Start Date: 12/04/2018 Related Announcements NOT-NS-18-057 NOT-NS-18-069 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) intends publish Funding Opportunity Announcement FOA) solicit applications a Clinical Coordinating Center CCC) a new Clinical Trials Network Pain Research CTNPR).  CTNPR part the NIH Helping End Addiction Long-Term HEAL) Initiative. network be charged testing novel, non-addictive treatments patients suffering acute chronic pain conditions. CTNPR harness multidisciplinary expertise pain science clinical research collaboratively design conduct Phase 2 multicenter clinical trials testing novel pain treatments. will also perform validation studies biomarkers promise inform target engagement proof principle Phase 2 clinical trials.  CTNPR develop deeply phenotyped cohorts specific acute chronic pain conditions adults children. The emphasis the CTNPR be pain conditions high unmet needs. Interventions be studied include drugs, biologics, devices, natural products surgical procedures.  CTNPR be composed one CCC, Data Coordinating Center DCC), approximately 10 clinical centers Hubs).  Hubs be Centers Excellence physicians pain expertise neurology, anesthesiology, rheumatology, physical medicine, obstetrics/gynecology, pediatrics, orthopedics, gastroenterology, other subspecialties providing care patients pain.  Hub envisioned as regional medical center will enroll patients along its network 2-10 satellite sites Spokes).    CCC the leaders the Clinical sites play critical role designing clinical trial protocols be conducted the CTNPR. Interventions be solicited a variety sources including pharmaceutical industry, medical device companies, academics.  will prioritized a separate NIH scientific review committee.  most promising interventions be assigned the CCC the CTNPR leadership will work outside investigators—including those the HEAL Public-Private Partnership—to develop innovative Phase 2 clinical trial protocols test highest priority tailored interventions patients specific pain conditions. CCC will provide scientific organizational leadership the CTNPR.  CCC the administrative center the CTNPR, responsibilities contracts sites performance clinical trials studies (master trial agreements the clinical centers, entities), planning budgets proposed clinical trials, disbursing payments sites. CCC leads manages key CTNPR governance committees. CCC primary responsibility identifying the central IRB.  The CCC responsible oversight all aspects trial enrollment recruitment, feasibility assessment, planning, tracking and, necessary, improvement plans.  CCC also responsible quality assurance related clinical trials to overall performance the CTNPR. CCC collaborate closely the DCC, clinical research sites, the clinical trial PDs/PIs with goal accelerating discovery evaluation treatments pain. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA expected be published July 2018 an expected application due date September 2018. FOA utilize U24 activity code. Details the planned FOA provided below. Research Initiative Details Notice encourages investigators appropriate expertise begin consider applying this new FOA. PD/PI the Clinical Coordinating Center CCC) must a clinical trials expert has successfully coordinated implemented multicenter clinical trials. Experience neurology pain clinical trials especially relevant.  Since CCC PD/PI the chair several CTNPR governance committees, is important he she sufficient time attend actively contribute the committee meetings. Members the CCC research team might include: Experienced study coordinators and/or project managers, potentially areas subspecialty such recruitment interactions IRBs;   Experienced financial coordinator manager; Site Support Manager comparable staff training all Hubs, Spokes ad hoc clinical sites; Components the central IRB, such IRB chair, members, director; Liaisons the IRB clinical sites. Applications the CCC be solicited a separate FOA issued the same time the DCC FOA.  Awards a CCC a DCC not made the same PD/PI institution ensure data analyses performed independently. Funding individual studies be provided through individual study grants. Industry partnerships be encouraged.  Applications Hubs for clinical trials studies themselves be solicited future FOAs. Investigators the CCC institution apply a Hub award.  CCC a Hub the same institution should led separate PDs/PIs ensure the CCC activities the local Hub activities receive full attention to preserve needed firewalls. mentioned NOT-OD-18-181, any for-profit recipient funds shall subject a matching requirement funds documented in-kind contributions not less 50 percent the total funds awarded such entity. Funding Information Estimated Total Funding TBD Expected Number Awards 1 Estimated Award Ceiling TBD Primary CFDA Numbers 93.853 Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Nonprofit without 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) U.S. Territory Possession Indian/Native American Tribal Government than Federally Recognized) Regional Organization Applications not being solicited this time. Inquiries Please direct inquiries to: Jeremy Brown, MD National Institute Neurological Disorders Stroke NINDS) 301-827-8375 Jeremy.Brown@nih.gov

Notice Intent Publish Funding Opportunity Announcement Clinical Centers the Clinical Trials Network Pain Research CTNPR) U24 Clinical Trial Allowed) Notice Number: NOT-NS-18-069 Key Dates Release Date:June 14, 2018 Estimated Publication Date Funding Opportunity Announcement: 07/16/2018 First Estimated Application Due Date: 09/14/2018 Earliest Estimated Award Date: 12/04/2018 Earliest Estimated Start Date: 12/04/2018 Related Announcements NOT-NS-18-057 NOT-NS-18-058 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke intends publish Funding Opportunity Announcement FOA) solicit applications a Clinical Trials Network Pain Research CTNPR). network be charged executing trials high impact the treatment patients acute chronic pain. CTNPR part the NIH Helping End Addiction Long-Term HEAL) Initiative. network be composed a Clinical Coordinating Center CCC), Data Coordinating Center DCC), ten Regional Clinical Centers together their linked clinical sites. purpose this notice to allow potential applicants sufficient time develop meaningful collaborations projects the clinical centers ("Hubs") CTNPR.  The CTNPR enable exploratory clinical trials investigational drugs biologics, investigational devices, natural products, surgical procedures the treatment pain.  These trials validate biomarkers, provide proof mechanism, otherwise contribute the justification proceeding not proceeding a future Phase 3 trial e.g., informing go/n-go decisions).  specific pain conditions include well-defined ones high unmet needs more common, chronic neuropathic, inflammatory nociceptive pain disorders adult pediatric populations. network focus multi-site Phase 2 trials.  The network also implement clinical studies biomarker discovery validation, will store biomarker data samples future biomarker discovery.  is anticipated the CTNPR be able run many five Phase 2 trials concurrently addition biomarker validation studies. The CTNPR consist one Clinical Coordinating Center CCC), Data Coordinating DCC), 10 clinical centers Hubs).   Hub be center excellence physician expertise neurology, anesthesiology, rheumatology, obstetrics/gynecology, pediatrics, orthopedics, physical medicine, gastroenterology, other subspecialties providing care patients pain.  Hub envisioned as regional medical center will enroll patients along its network 2-10 satellite sites Spokes). A Hub additionally provide scientific leadership administrative oversight its multiple satellite sites ("Spokes").  notice solicits applications the CTNPR Clinical Centers. Separate notices been issued the Clinical Coordinating Center the Data Coordinating Center NOT-NS-18-058 NOT-NS-18-057). Interventions trials within CTNPR be solicited the national scientific community.  CTNPR design execute trials investigational drugs, devices biologics provided companies academics. FOA expected be published July 2018 an expected application due date September 2018. FOA utilize U24 activity code. Research Initiative Details Hub must a flexible network Spokes.  principal function the Spokes to provide access a larger patient population trial enrollment. Spokes also increase access patients a particular disease syndrome, patients underserved communities, complement Hub providing access specific research clinical expertise.  each clinical trial, Hub be expected construct network 2-10 Spokes specifically tailored the needs that particular trial. Since requirements each clinical trial be somewhat different, identity configuration Spokes be unique each trial.  Therefore, Hub should relationships a number potential Spokes, the ability add Spokes appropriate.  demonstrate ability attract Spokes, applicant requested identify the grant submission five Spokes committed participation at least clinical trial.   Since five Spokes unlikely meet possible clinical trial requirements, Hub need have plans mechanisms recruiting adding Spokes, needed. mentioned NOT-OD-18-181, any for-profit recipient funds shall subject a matching requirement funds documented in-kind contributions not less 50 percent the total funds awarded such entity. Funding Information Estimated Total Funding TBD Expected Number Awards TBD Estimated Award Ceiling TBD Primary CFDA Numbers TBD Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Nonprofit without 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) Indian/Native American Tribal Government than Federally Recognized) Regional Organization Applications not being solicited this time. Inquiries Please direct inquiries to: Jeremy Brown MD National Institute Neurological Disorders Stroke NINDS) 301-827-8375 jeremy.brown@nih.gov

Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional). Notice Number: NOT-NS-18-072 Key Dates Release Date: June 14, 2018 Related Announcements NOT-NS-20-085 PAR-18-657 Issued National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to amend award budget PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)." Section II. Award Information Currently Reads: Award Budget Application budgets not exceed 2.5 million direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. Modified Read: Award Budget Application budgets not exceed $2.0 million in direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. other aspects this FOA remain same. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone:  301-496-6035 Email: jettd@ninds.nih.gov

Notice New Budget Limitation PAR-16-331 Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01) Notice Number: NOT-NS-18-071 Key Dates Release Date: June 12, 2018 Related Announcements PAR-16-331 Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to amend award budget PAR-16-331 Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01)." Section II. Award Information Currently Reads: Award Budget Application budgets not limited, need reflect actual needs the proposed project. most applications within scope this FOA, expected direct cost individual awards 300,000-$500,000 per year. applications not need request maximum budget the size duration the awards vary depending upon nature scope research programs. Modified Read: Award Budget Application Budget not exceed $500,000 in direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. other aspects this FOA remain same. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone:  301-496-6035 Email:  jettd@ninds.nih.gov nbsp;

Notice Correction Key Dates RFA-NS-18-029 BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP U01 Clinical Trial Allowed) Notice Number: NOT-NS-18-070 Key Dates Release Date: 23, 2018 Related Announcements RFA-NS-18-029 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a correction the Key Dates RFA-NS-18-029 BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP U01 Clinical Trial Allowed)".  Specifically, Advisory Council Review dates January 2019 and January 2020 and Earliest Start Dates February 2019 and February 2020. Part 1. Overview Information Key Dates Currently Reads: Advisory Council Review January 2019 Earliest Start Date February 2019 Modified Read: Advisory Council Review January 2019 and January 2020 Earliest Start Date February 2019 and February 2020 other aspects this FOA remain same. Inquiries Please direct inquiries to: James Gnadt, PhD  National Institute Neurological Disorders Stroke NINDS)  Telephone: 301-496-9964  Email: BRAINCircuits@nih.gov

Second Round the NIH Applicant Assistance Program AAP) New Previously Unawarded Small Businesses Notice Number: NOT-CA-18-072 Key Dates Release Date: 14, 2018 Related Announcements NOT-CA-18-031 Issued National Cancer Institute NCI) National Heart, Lung, Blood Institute NHLBI) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to announce second round a pilot program assist eligible small businesses understanding completing Small Business Innovation Research SBIR) Small Business Technology Transfer STTR) application process. program, NIH Applicant Assistance Program AAP), intended help new and/or previously unsuccessful small businesses submit competitive SBIR STTR application one the participating institutes NCI, NINDS, NHLBI).   AAP designed to: Provide support small businesses preparing Phase SBIR STTR application Assist identifying appropriate market research an SBIR/STTR application Guide applicants through application process, including required registrations Help applicants the electronic system apply an SBIR/STTR award   NIH particularly interested assisting small businesses are owned operated individuals are underrepresented the biomedical sciences, including: Black African Americans Hispanics Latinos American Indians Alaska Natives Native Hawaiians other Pacific Islanders Individuals disabilities Women underrepresented biomedical industry ownership high-level leadership)   service provided through third-party federal contractor. Small businesses must apply be accepted the NIH AAP. After acceptance, program offered no charge the small business. Participation this program optional does guarantee successful SBIR STTR award. Small businesses interested the program apply here: https://www.dawnbreaker.com/aap/   second round the NIH AAP the final round the pilot program. deadline apply the NIH AAP Friday, June 1, 2018. Applicants applied the first round the pilot program were selected need apply the second round their application be considered. Inquiries Please direct inquiries to: Kory Hallett, PhD National Cancer Institute NCI) Telephone: 240-276-5882 Email: kory.hallett@nih.gov   Stephanie Fertig, MBA National Institute Neurological Disorders Stroke NINDS) Telephone 301-496-1779 Email: fertigs@ninds.nih.gov   Eric Padmore, MHSA National Heart, Lung, Blood Institute NHLBI) Telephone: 301-496-2149 Email: NHLBI_SBIR@mail.nih.gov

Notice Support Administrative Supplements Embed Ethicists BRAIN Initiative Supported Research Notice Number: NOT-MH-18-034 Key Dates Release Date: 01, 2018 Related Announcements None Issued National Institute Mental Health NIMH) National Eye Institute NEI) National Institute Aging NIA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) Purpose Brain Research through Advancing Innovative Neurotechnologies BRAIN) Initiative aimed revolutionizing neuroscience through development application innovative technologies map neural circuits, monitor modulate activity, understand they contribute thoughts, sensations, emotions behavior. NIH issued variety Funding Opportunity Announcements FOAs) will support projects apply technologies understand neural circuit function the context specific circuits, resulting a diverse portfolio research the fundamental biology nervous system function.  purpose this announcement to notify research community NIH encouraging applications to PA-18-591 to integrate neuroethics perspectives approaches existing BRAIN Initiative awards. Supplement applications encouraged ongoing BRAIN Initiative projects can readily incorporate core ethical issues associated research focused the human brain resulting emerging technologies advancements research development supported the BRAIN Initiative. intent that efforts supported through administrative supplement be both complimentary integrative the transformative, breakthrough neuroscience discoveries supported through BRAIN Initiative.   an administrative supplement, work proposed needs be within scope the research is already supported. Research proposed supplement applications should clear relevance the BRAIN Initiative. proposed work cover pilot projects, resource development, personnel costs embedding neuroethics the research project. each case, work proposed should feasible complete within one-year timeframe with limited funds permitted. should also show promise becoming more substantial project might attract additional funding. Investigators should submit applications responses the parent active administrative supplement announcement https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html) using electronic submission. Electronic applications strongly encouraged.. Individual requests be more 100,000 direct costs exclusive Facilities Administrative costs sub-contracts may for year only. Requests must received June 15 funding FY 2018. Inquiries Please direct inquiries to: James Churchill National Institute Mental Health NIMH) Telephone: 301-443-3621 Email: churchillj@mail.nih.gov 

NINDS Announces Modifications Special Council Review Policy Notice Number: NOT-NS-18-060 Key Dates Release Date: April 27, 2018 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice announces modifications the Special Council Review SCR) policy, pertains well-funded Program Director(s)/Principal Investigator(s) PD(s)/PI(s)] submitting applications NINDS.  new policy: 1) lowers funding threshold requires special review a pending application the National Advisory Neurological Disorders Stroke NANDS) Council and; 2) sets more stringent payline pending applications cause PD/PI exceed threshold. Background September 2012, NIH implemented SCR policy, whereby Advisory Councils instructed provide additional scrutiny new renewal applications investigators already receiving 1.0M more direct cost NIH Research Project Grant RPG) funding.  2012 NIH policy recognized institute-specific variations the general policy be developed consultation individual Councils.   NANDS Council discussed NIH policy its September 2017 February 2018 meetings, approved modified policy described here.  goals this policy are: 1) permit Institute fund larger, diverse pool researchers 2) ensure PIs sufficient bandwidth oversee rigorous research effective mentorship their laboratories.   Policy Effective applications under funding consideration the January 2019 meeting the NANDS Council, NINDS refine Special Council Review policy procedures support research well-funded investigators.  Under new policy, well-funded investigator defined an individual NIH research support exceeding 1M direct costs the time the Council meeting, including pending application.  the purposes this policy, only research support which investigator the PI Co-PI be considered.  competing applications well-funded investigators primary assignment NINDS exceptions noted below) be subject a percentile payline is ½ the NINDS payline the Council round question https://www.ninds.nih.gov/Funding/About-Funding/NINDS-Funding-Strategy; the payline an odd number, SCR payline be rounded down the next integer. questions applications are percentiled, applicants should contact individual noted below further information.  Exceptions this policy be rare, will determined after review NINDS staff, NANDS Council, NINDS leadership. contrast the existing SCR policy, competing applications P01s, Centers, other Multi-Component RPGs be included this policy.  Multi-PD/PI projects also subject the policy one more the PD/PIs NIH research support exceeding 1.0M inclusive the pending application.  Applications will excluded this policy include those intended support training, conferences, core facilities, research resources.  Applications submitted response SBIR/STTR solicitations to small number specially designated Funding Opportunity Announcements also excluded. identifying well-funded investigators, active NIH research support be considered except awards support training, conferences, core facilities, research resources, SBIR/STTR activities.  individual PD/PI’s financial allocation Multi-PD/PI multi-component projects be used determine individual’s level support. Grants are a no-cost extension single year competitive administrative supplements not included this determination. Factors may contribute a funding recommendation beyond SCR payline include conducting types research are inherently costly, PD/PI’s available bandwidth commit time effort commensurate the application’s complexity scope, the type, source end dates the PD/PI’s NIH support.  PDs/PIs be permitted temporarily exceed 1M threshold a period no than 90 days ensure continuity funding support. PDs/PIs also discontinue previously funded grants begin work the new project. Please visit NINDS website additional details a list Frequently Asked Questions. NINDS recognizes this policy change research plans some laboratories, the intent to advance mission the Institute supporting larger, diverse group investigators. Inquiries Please direct inquiries to: Anna Taylor, Ph.D. National Institute Neurological Disorders Stroke Telephone: 301-827-3565 Email: taylorann@mail.nih.gov

Notice Availability Administrative Supplements Secondary Analysis Existing Datasets within Rare Diseases Clinical Research Network RDCRN) Explore Outcomes Relevant Rare Diseases Notice Number: NOT-TR-18-019 Key Dates Release Date: April 25, 2018 Related Announcements PA-18-591 Issued National Center Advancing Translational Sciences NCATS) National Heart, Lung, Blood Institute NHLBI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Neurological Disorders Stroke NINDS) Purpose National Center Advancing Translational Science NCATS) announces opportunity investigators relevant active Rare Diseases Clinical Research Consortia RDCRC) Rare Diseases Clinical Research Network RDCRN) U54) submit administrative supplement requests the NIH Parent Funding Opportunity Announcement FOA), Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional)” PA-18-591 .   is vitally important begin use existing RDCRC datasets they intended: through secondary analyses develop new hypotheses Rare Diseases outcomes; such identify particular vulnerabilities specific populations; explore age, sex racial differences may warrant larger studies; discover new treatment/rehabilitation approaches; reveal correlations among outcomes outcome domains can guide future studies.   goal to existing human datasets well-focused secondary analyses investigate novel scientific ideas new models, systems, tools, methods, technologies have potential significant impact biomedical biobehavioral research areas relevant the RDCRN’s mission. RDCRN's mission to foster development scientific knowledge needed enhance health, productivity, independence, quality-of-life individuals Rare Diseases. Program Director(s)/Principal Investigators PIs) strongly encouraged partner Early Stage Investigators ESIs).  Projects must propose collect new data must within scope the current award. Budget Available Funds Budgets limited no than 50K direct costs. Award Project Period Supplement project budget periods limited the remaining FY18 budget period.  be eligible, parent award must active i.e. be an extension period), the research proposed the supplement must accomplished within remaining active budget period started FY18 the existing parent award. earliest anticipated start date July 1, 2018. Review process Administrative Review be conducted a committee NIH RDCRN Program Officers/Program Directors final decisions by funding ICs Page Limit NCATS consider supplements a Research Strategy no than 3 pages. Submitting Application Applicants should begin application stating: application being submitted response NOT-TR-18-019".  additional information, the parent program announcement Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-591. Applications these administrative supplements due 5:00 PM local time June 8, 2018. Inquiries Please direct inquiries to: Tiina K. Urv, PhD National Center the Advancement Translational Science NCATS) Telephone: 301-827-2746 Email: urvtiin@mail.nih.gov

Notice Extend Expiration Date Change Receipt Dates PAR-16-458 NINDS Ruth L. Kirschstein National Research Service Award NRSA) Training Postdoctoral Fellows F32)" Notice Number: NOT-NS-18-061 Key Dates Release Date: April 23, 2018 Related Announcements PAR-16-458 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform interested applicants there be change receipt dates for Funding Opportunity Announcement FOA) PAR-16-458 NINDS Ruth L. Kirschstein National Research Service Award NRSA) Training Postdoctoral Fellows F32)" the expiration date be extended one receipt cycle.  Specifically, receipt dates requests submitted under FOA, PAR-16-458 change August 8, 2018, December 8, 2018, April 8, 2019, August 8, 2019 to June 20, 2018, October 18, 2018, February 15, 2019, and June 19, 2019and additional application due date, October 17, 2019, been added this FOA.  new expiration date this FOA is January 8, 2020. Part 1. Overview Information Key Dates Currently Reads: Application Due Date(s) Standard dates  apply (December 8, 2016, April 8, 2017, August 8, 2017, December 8, 2017, April 8, 2018, August 8, 2018, December 8, 2018, April 8, 2019, August 8, 2019) 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date September 8, 2019 Modified Read: Application Due Date(s) December 8, 2016, April 8, 2017, August 8, 2017, December 8, 2017, April 8, 2018, June 20, 2018, October 18, 2018, February 15, 2019, June 19, 2019, and October 17, 2019 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date January 8, 2020 other aspects this FOA remain same. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke Telephone: 301-496-188 Email: korns@mail.nih.gov